（文章来源：证券日报） 证券日报网讯 2月2日，本立科技在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东总 人数为9968户。 ...

格隆汇2月2日丨本立科技(301065.SZ)发布公告，公司董事会于近日收到公司副总经理盛孟均提交的书 面辞任报告。盛孟均因个人原因辞去公司副总经理职务，上述职务原定任期为2024年6月7日至2027年6 月6日，其辞职后不再担任公司任何职务。盛孟均的辞任报告自送达公司董事会之日起生效。 ...

根据《公司法》《深圳证券交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》等有关规定，盛孟均先生的辞任报 告自送达公司董事会之日起生效。盛孟均先生已按照公司《董事、高 级管理人员离职管理制度》的规定完成工作交接，其辞职不会对公司 正常生产经营产生影响。 截至本公告披露日，盛孟均先生直接持有公司股份225,000股 （占公司总股本的0.21%，占剔除公司回购专用证券账户股份数量后 总股本的比例为0.22%），通过台州少思投资合伙企业（有限合伙） 间接持有本公司股份262,500股（占公司总股本的0.25%，占剔除公司 回购专用证券账户股份数量后总股本的比例为0.25%）。辞职后，盛 孟均先生将继续遵守《上市公司董事和高级管理人员所持本公司股份 及其变动管理规则》《深圳证券交易所上市公司自律监管指引第18 号——股东及董事、高级管理人员减持股份》等相关法律法规有关规 定及本人在《首次公开发行股票并在创业板上市招股说明书》和《首 证券代码：301065 证券简称：本立科技 公告编号：2026-002 浙江本立科技股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确 ...

浙江本立科技股份有限公司（以下简称"公司"或"本立科技"） 于2025年12月10日披露了《关于高级管理人员减持股份预披露公告》 （公告编号：2025-046），公司副总经理盛孟均先生因个人资金需求 计划在上述公告披露之日起15个交易日后的3个月内以集中竞价交易 方式减持其直接持有的公司股份不超过75,000股，占公司总股本的 0.07%，占剔除公司回购专用证券账户股份数量后总股本的比例为 0.07%。 公司于近日收到高级管理人员盛孟均先生出具的《关于股份减持 计划实施完成的告知函》，截至本公告披露日，上述减持计划已累计 减持75,000股，占公司总股本的0.07%，上述减持计划已实施完毕。 现将本次减持计划实施情况公告如下： 证券代码：301065 证券简称：本立科技 公告编号：2026-001 浙江本立科技股份有限公司 关于高级管理人员减持计划实施完成的公告 公司副总经理盛孟均先生保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、股东减持情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持 ...

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

Core Viewpoint - The company has obtained its first "Drug Production License" from the Zhejiang Provincial Drug Administration, which is expected to optimize its product structure and positively impact long-term development [1] Group 1: License Acquisition - The acquisition of the "Drug Production License" marks the company's first achievement in this area [1] - The license will facilitate the optimization of the company's product structure [1] Group 2: Future Steps - The company must complete registration, on-site verification, and obtain raw material drug filing approval before commercial production and sales can commence [1] - The immediate impact of the license on the company's operating performance is expected to be minimal [1]

Core Viewpoint - The company has recently obtained a "Drug Manufacturing License" issued by the Zhejiang Provincial Drug Administration, which is valid until December 29, 2030, and will enhance the company's product structure and long-term development [1] Group 1 - The license allows the company to produce active pharmaceutical ingredients [1] - The production site is located at No. 15, East Sea Sixth Avenue, Tumen Port New District, Linhai, Zhejiang Province [1] - The acquisition of the license is expected to positively impact the company's long-term growth [1]

关于公司取得《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江本立科技股份有限公司（以下简称"公司"）于近日取得了 由浙江省药品监督管理局颁发的《药品生产许可证》，现将相关信息 公告如下： 一、《药品生产许可证》的基本信息 企业名称：浙江本立科技股份有限公司 社会信用代码：913310005753258189 证券代码：301065 证券简称：本立科技 公告编号：2025-047 浙江本立科技股份有限公司 许可证编号：浙20250019 分类码：Dh 日常监督管理机构：浙江省药品监督管理局 注册地址：浙江省临海头门港新区东海第六大道15号 法定代表人：吴政杰 企业负责人：吴政杰 质量负责人：罗臣 有效期至：2030年12月29日 生产地址和生产范围：浙江省临海头门港新区东海第六大道15号： 原料药*** 二、对公司的影响及风险提示 本次系公司首次取得《药品生产许可证》，有利于优化公司产 品结构，对公司长远发展有着积极的推动作用。公司尚须通过注册 申报、现场核查等监管程序并取得原料药备案证明后，方可上市进 行商业化生产销售。《药品生产 ...

Group 1 - The core viewpoint of the news is that Benli Technology has shown significant trading activity with a notable increase in financing and a mixed performance in revenue and profit [1][2]. Group 2 - As of December 23, Benli Technology's stock price decreased by 0.42%, with a trading volume of 24.74 million yuan [1]. - The financing data indicates that on the same day, the company had a financing buy amount of 3.88 million yuan and a net financing buy of 1.76 million yuan, with a total financing balance of 81.21 million yuan [1]. - The financing balance represents 3.62% of the circulating market value and is above the 80th percentile level over the past year, indicating a high level of financing activity [1]. Group 3 - The company reported a total revenue of 481 million yuan for the period from January to September 2025, reflecting a year-on-year decrease of 10.67%, while the net profit attributable to the parent company was 55.78 million yuan, showing a year-on-year increase of 10.67% [2]. - The total cash dividends distributed by Benli Technology since its A-share listing amount to 66.29 million yuan, with 41.55 million yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders include a new institutional shareholder, Nuoan Multi-Strategy Mixed A, holding 700,000 shares [3].

Group 1 - The core point of the article is that Benli Technology (301065) reported a total of 10,274 shareholders as of December 19, 2025 [1]